Alkem Laboratories launches antibiotic medication for multiple drug resistance infections

31 Jan 2023 Evaluate

Alkem Laboratories has launched an antibiotic drug to treat multiple drug resistance infections. The company's product Zidavi is a novel combination of ceftazidime & avibactam and is indicated for various ailments like complicated urinary tract infections.

With the rise in infections caused by carbapenem-resistant Gram-negative organisms in India, there is a need for more effective antibiotic treatment. The available evidence suggests that Zidavi (ceftazidime-avibactam) is a potential therapeutic option for the treatment of infections complicated by multi-drug resistant (MDR) organism.

Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.

Alkem Laboratories Share Price

4719.00 7.10 (0.15%)
25-Apr-2024 10:03 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1508.00
Dr. Reddys Lab 5965.00
Cipla 1393.10
Zydus Lifesciences 933.45
Lupin 1590.80
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.